Registration: 10-30 AM - 11 AM

Panel Discussions and Keynotes: 11 AM - 6-30 PM

Cocktails and Networking Reception: 6-30 PM - 8 PM

* Timings subject to change

1. Industry-Academia Partnerships: Is there a better prescription to create value?
   Overall objective: With increasing models of cross-border industry-academia collaborations, this panel will highlight opportunities for Indian and US industry to work with Indian and US academia to accelerate drug discovery and innovation.
   
   Key issues to highlight
   
   1. How to leverage the knowledge, assets and best practices of different stakeholders (US and Indian industry; US and Indian academia)?
   2. What have been some experiences and models that have already shown success?
   3. What additional training or capacity building is required in the areas of Drug discovery, Development and Healthcare where future partnerships could be valuable?
   4. What are potential roadblocks including IP sharing issues , patent pooling (?) for products for developing countries, access to Indian universities?
   5. Are there other countries that do this better than India? We have great universities in India but are they good at cross-border collaboration?
   6. How connected do US Universities feel with Indian healthcare and Indian industry? What would better facilitate that?
   7. How connected do US Biopharma R&D organizations feel with Indian academia? What would better facilitate that?
   8. As part of the Healthcare Reform legislation, the U.S. Government has infused new resources into "comparative effectiveness" research. Are there opportunities for partnership between U.S. academic institutions that have strengths in this area and their Indian counterparts?
   
   
2. Increasing the odds of success : Collaborative research and drug discovery
   Overall objective: With the rapidly increasing volume and value of US-India deals, this panel will talk about the next level of partnership and collaborative research, ranging from fee for service, performance based to co-development. It will highlight approaches to take these partnerships to the next level.
   
   Key issues to highlight
   
   1. What can we learn from past partnerships?
   2. How have the different panelists forged relationships of trust?
   3. Are there more creative models that could be pursued (e.g. innovative licensing deals, a special investment fund for Indian assets)?
   4. Is there a role that the government can play to be helpful or is this largely a B2B opportunity (e.g. better biotech parks)?
   5. In drug discovery, India/Indian companies have largely played a role in reducing cost. How can they also play a role in reducing attrition more directly?
   6. How can the US Biopharma R&D organizations move towards strategic partnerships with Indian partners rather than principal-vendor relationships?
   
   
3. Moving the needle on Drug Development, Clinical Research and other Healthcare opportunities
   Objective: Drug development represents 50% of the R&D cost base. Over the last decade timelines have increased and costs have sky rocketed. This is also an area where there has already been double digit growth in Indian trial volume. On that platform, this panel will investigate how we can collaborate to deliver drugs on time at lower cost without compromising on quality.
   
   Key issues to highlight
   
   1. What is the incremental opportunity to do more trials in India?
   2. Should pharmacos and CROs develop deeper, direct relationships with megasites and hospitals?
   3. How to better train and cultivate talent (e.g. through industry consortiums)?
   4. How to ensure there is a framework for supporting regulations?
   5. What do pharmacos value the most from Indian trial partners (e.g. project management; TA depth; attention to detail; promptness etc.)?
   6. What are other roadblocks and how to overcome them?
   7. How can the US institutions help the Indian healthcare and delivery system?
   
   
4. "Show me the Money": Funding innovation, investment opportunities and cross border M&A trends in US-India BioPharma & Healthcare.
   Objective: It's not all about the money - but without money there wouldn't be discovery. In the last few years there has been significant PE, VC money by way of funds dedicated to India or more broadly emerging markets. This panel will focus on what investors like about US-India M&A and investment opportunities, and what they wish they could see more of.
   
   Key issues to highlight
   
   1. How is the investor base looking at different opportunities, and what would they would like to see more of?
   2. Which types of transactions and investments have they seen the most value come from?
   3. What are some learnings from the recent crisis and how are they are adapting their investment or acquisition philosophies?
   4. Do they see an opportunity for more large, RBX like deals?
   5. Do they wish that India had a Sovereign Wealth fund? What would that do?
   6. What is the role of government policies to fund innovation and provide seed money?
   7. What are the opportunities for Indian companies to acquire assets of small start-up/innovative companies to take them to the next level due to scarcity of VC funds?

Agenda

• Drug Discovery, Development, Clinical Research, In/Out Licensing, Regulatory Issues
• Industry-Academic Partnerships
• Healthcare Opportunities and Challenges
• Funding innovation, Cross Border Investments and M&A trends in the US-India Biotech, Pharmaceuticals and Healthcare
• Focus on senior management issues
• Actions by the Indian government to support innovation through policy, infrastructure initiatives and financial incentives
• Overall impact on US-India collaborations and investments

Lunch, Cocktails & High Power Networking Reception